Trials / Completed
CompletedNCT02660944
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Resolve Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RSLV-132 | RNase-Fc fusion protein |
| DRUG | Placebo | Saline placebo |
Timeline
- Start date
- 2016-01-03
- Primary completion
- 2020-05-28
- Completion
- 2020-08-10
- First posted
- 2016-01-21
- Last updated
- 2021-03-10
- Results posted
- 2021-03-10
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02660944. Inclusion in this directory is not an endorsement.